Summary & Overview
HCPCS Level II J1326: Injection, zolbetuximab-clzb, 2 mg
HCPCS Level II code J1326 denotes a 2 mg unit of zolbetuximab-clzb administered by injection. Zolbetuximab is a monoclonal antibody used in oncology, and its HCPCS coding is important for standardized billing, benefit administration, and national tracking of biologic oncology therapies. Nationally, accurate use of J1326 affects claims processing, patient cost-sharing, and coverage determinations for specialty oncology drugs.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise outline of what the code represents, the typical clinical setting for administration, and which major payers are considered. The publication also covers benchmark-oriented topics such as reimbursement considerations across major payers, policy updates relevant to HCPCS-coded biologics, and clinical context for infusion-based oncology therapy.
This analysis provides practical reference material for billing teams, revenue cycle staff, and policy analysts seeking clarity on coding and payer coverage discussions for injectable oncology biologics. Data not available in the input is noted where applicable in supporting sections.
Billing Code Overview
HCPCS Level II code J1326 describes an injection of zolbetuximab-clzb, 2 mg. This code represents a single unit dosage of the monoclonal antibody zolbetuximab administered by injection. The service type is an injectable biologic oncology therapy. The typical site of service for administration is an outpatient infusion center or hospital outpatient department.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with advanced or metastatic gastric adenocarcinoma that is claudin 18.2-positive presents to the oncology infusion center for administration of targeted monoclonal antibody therapy. The medication J1326 represents zolbetuximab-clzb, supplied and billed per 2 mg unit. Prior to infusion, the patient undergoes verification of identity, review of recent labs (complete blood count, basic metabolic panel, liver function tests), allergy screening, and review of prior imaging and pathology confirming claudin 18.2 expression. The oncology nurse prepares the dose based on weight and the manufacturer’s dosing regimen, performs standard pre-medication (as clinically indicated) and intravenous access placement, and initiates infusion under oncology nursing and physician oversight. During the infusion, the patient is monitored for infusion-related reactions, vital signs are recorded at defined intervals, and any adverse events are documented. Post-infusion instructions and scheduling for subsequent cycles are provided. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic. Service type is therapeutic intravenous infusion of a monoclonal antibody, billed as drug supply using HCPCS level II code J1326 per 2 mg.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |